EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPTBiotechnology
+$0.26 today
- Market cap
- $250.69M
- Beta
- 1.75
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$3.16
Volume 2.75M
Average 0.95M
EYPT Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
EyePoint Pharmaceuticals, Inc.NASDAQ: EYPT
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital dips below year-ago levels
Q1 FY2026 change in working capital of $7.21M (cash outflow) fell 50.3% year over year, behind the +1949.9% change in trailing-twelve-month change in working capital. Sequentially, it rose 67.3% from the prior quarter. Over 3 fiscal years it compounded at +123.6% a year.
Context
- Change in working capital amounted to 107.7% of revenue in FY2025, up 43.5 pp from a year earlier.
- Change in working capital increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -50.3% toward the trailing-twelve-month pace of +1949.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (33.78M) USD
- Year-over-year change
- -21.6%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.78M) | -21.6% |
| FY2024 | 2024-12-31 | (27.77M) | -147.2% |
| FY2023 | 2023-12-31 | 58.88M | +2047.8% |
| FY2022 | 2022-12-31 | (3.02M) | -73.8% |
| FY2021 | 2021-12-31 | (1.74M) | — |
Change in Working Capital vs competitors
How EYPT compares with its peers on the latest reported figures
- EYPT's LTM Mar 2026 change in working capital of $26.49M is the 3rd largest of the 11 companies compared; the peer median is $866.5K.
- Its year-over-year change of +1949.9% is the highest of 11, against a peer median of -71.5%.
- Change in working capital amounts to 347.8% of revenue for EYPT, versus a peer median of 7.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $158.92M | -40.1% | — | 221.8% | |
| LTM Aug 2026 | $50.82M | +271.7% | +18.4% | 7.2% | |
| LTM Mar 2026 | $26.49M | +1949.9% | +123.6% | 347.8% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $21.87M | +483.9% | +44.1% | — |
SEPNSepterna, Inc. | LTM Sep 2026 | $6.99M | -104.2% | +353.4% | 7.3% |
| LTM Mar 2026 | $5.09M | -146.7% | — | 572.0% | |
| LTM Sep 2026 | $4.43M | -44.9% | -17.0% | — | |
| LTM Mar 2026 | $3M | -237.1% | — | — | |
| LTM Mar 2026 | $1.92M | +1599.1% | +73.4% | — | |
| LTM Sep 2026 | $1.38M | -98.2% | +53.7% | — | |
| LTM Mar 2026 | $187K | -100.3% | -46.8% | 4.6% | |
| Peer median (excluding EYPT) | $866.5K | -71.5% | +44.1% | 7.3% | |
Competitors are the stored peer set for EYPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.42M) | (102.25M) | (70.8M) | (130.87M) | (231.96M) |
| Depreciation & Amortization | 2.77M | 2.45M | 464K | 1.54M | 2.31M |
| Deferred Income Tax | (787K) | 0 | 83K | 90K | 279K |
| Stock-Based Compensation | 7.45M | 14.18M | 12.06M | 36.74M | 27.87M |
| Change in Working Capital | (1.74M) | (3.02M) | 58.88M | (27.77M) | (33.78M) |
| Accounts Receivables | (10.6M) | (2.66M) | 14.43M | (244K) | (10.67M) |
| Inventory | 1.35M | (760K) | (1.55M) | 1.6M | 492K |
| Accounts Payables | 8.48M | 1.2M | 1.52M | 5.73M | 4.68M |
| Other Working Capital | (959K) | (799K) | 44.48M | (34.86M) | (28.28M) |
| Other Non-Cash Items | 628K | 23.65M | 1.18M | (5.95M) | (4.83M) |
| Operating Cash Flow | (50.1M) | (65.01M) | 1.88M | (126.23M) | (240.11M) |
| Capital Expenditures | (156K) | (2.15M) | (3.48M) | (4.05M) | (3.28M) |
| Acquisitions (Net) | 0 | (558K) | (168K) | 0 | 155K |
| Purchases of Investments | (32.97M) | (139.12M) | (55.12M) | (398.3M) | (252.02M) |
| Sales of Investments | 0 | 124M | 55.28M | 177.05M | 318.9M |
| Other Investing Activities | 0 | 558K | 168K | 5.95M | 4.83M |
| Investing Cash Flow | (33.12M) | (17.27M) | (3.32M) | (219.36M) | 68.58M |
| Debt Repayment | (146K) | 2.1M | (40.51M) | (105K) | (105K) |
| Common Stock Issued | 216.83M | 395K | 226.17M | 163.31M | 175.14M |
| Common Stock Repurchased | 0 | (295K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 223K | (3.19M) | 1.41M | 813K | (1.39M) |
| Financing Cash Flow | 216.9M | (690K) | 187.07M | 164.02M | 173.65M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 133.68M | (82.96M) | 185.63M | (181.56M) | 2.12M |
| Free Cash Flow | (50.25M) | (67.16M) | (1.61M) | (130.28M) | (243.39M) |
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
Intrinsic Alpha fair value
Locked
Current Price
$2.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.